Retrospective analysis sought to determine incidence of hip and vertebral fractures in patients with MPN compared with that of the general population.
Interferon-alpha and pegylated interferon-alpha, as well as hydroxyurea and anagrelide, represent cytoreductive approaches to the treatment of patients with ET and PV.
Germline polymorphisms can affect response to treatment in people with polycythemia vera.
Researchers sought to markers that could identify high risk for splanchnic vein thrombosis among patients with MPNs.
Spleen stiffness was found to be correlated with the extent of bone marrow fibrosis, as well as clinical outcome, in patients with MPNs.